Dicot Deepens Management Team with new CFO/Director of Investor Relations

Press release: Uppsala, June 25, 2019. Dicot AB (publ, developer of drugs targeting sexual dysfunction, today announced that the company has contracted Julie Silber as its new CFO and Director of Investor Relations, effective June 25, 2019. In this role, Silber will be responsible for leading financial strategies, including overseeing accounting, internal audit, investor relations and corporate communications. Silber will succeed Bengt Norvik, who will remain with the company until the end of June to ensure a smooth transition.

"I am pleased to welcome Julie to Dicot. Julie not only has a solid record of implementing financial and corporate strategy, her background and skills are in line with Dicot's near and long-term strategic goals at this important time in the company's history," says Göran Beijer, CEO. "I would also like to thank Bengt for his diligent work in helping bring Dicot to where we are today," continued Beijer.

Julie Silber brings over 20+ years of financial experience including executive financial leadership roles with both private and publicly held companies, several years of CFO level experience, several years as a for-hire equity analyst and over 10+ years as an IRO. Since moving to Sweden, Julie has specialized in gaining visibility and positioning smaller, Life Science companies to the global financial markets. She holds a bachelor"s degree in International Relations from the University of Southern California, a certificate in Accounting from the Center for Non-Profit Management and a master's degree in Environmental Science & Policy, also from USC. 

For more information, please contact:

Julie Silber 

CFO/Investor Relations Director, Dicot 

Tel.: +46-79-3486277 

Email: [email protected] 

About Dicot AB: 

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, LibiguinTM, for the treatment of sexual dysfunctions and is in preclinical. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. www.dicot.se

Attached files


Om Dicot Pharma

Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.



Kurs ()
Förändring ()
Marknad Spotlight Stock Market Kortnamn DICOT ISIN-kod SE0011178458


Elin Trampe Vd